Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents

This study has been completed.
Sponsor:
Collaborators:
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00272233
First received: January 3, 2006
Last updated: March 19, 2007
Last verified: January 2006
  Purpose

Work requirements for medical trainees result in substantial sleep loss. Sleep loss has been associated with increased levels of certain inflammatory hormones that could have negative impact on blood vessel function. The purpose of this study is to determine the effects of sleep loss on blood hormone levels and blood vessel function in medical trainees.


Condition Phase
Sleep Deprivation
Phase 1

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents

Further study details as provided by Yale University:

Estimated Enrollment: 22
Study Start Date: December 2004
Estimated Study Completion Date: June 2005
Detailed Description:

Context: Sleep loss is associated with increased blood levels of interleukin-6 (IL-6) and C-reactive protein (CRP). Medical residents are often deprived of normal sleep during extended work shifts, but the effects of work-related sleep loss on biomarkers of vascular inflammation and function are unknown.

Objective: We sought to test the hypothesis that sleep loss during extended work shifts during medical training is associated with increased circulating levels of pro-inflammatory biomarkers and evidence of vascular dysfunction.

Design: Outcome measures were assessed after extended 30-hour work shifts and non-extended 6-hour work shifts in a single-blind, randomized crossover design.

Setting: University hospital medical intensive care unit

Patients or Other Participants: Twenty-two healthy medical residents were studied during a medical intensive care unit rotation.

Main Outcome Measure(s): Sleep related cytokines (interleukin-6 and tumor necrosis factor), serum markers of vascular inflammation (C-reactive protein), and flow-mediated dilation in the brachial artery.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Medical resident in MICU rotation
  • Non-smoker
  • Body mass index <28 kg/m2

Exclusion Criteria:

  • Systolic blood pressure >140 mmHg; Diastolic blood pressure >90 mmHg
  • Known history of diabetes mellitus, hypertension, hyperlipidemia
  • Known history of acute or chronic inflammatory or infectious disease
  • Known history of sleep disturbance unrelated to work
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00272233

Locations
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Stuart D Katz, MD Yale University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00272233     History of Changes
Other Study ID Numbers: HIC26414, NIH NHLBI K24 04024
Study First Received: January 3, 2006
Last Updated: March 19, 2007
Health Authority: United States: Yale University School of Medicine
United States: National Heart Lung and Blood Institute

Keywords provided by Yale University:
Inflammation Mediators [D23.469]
Cardiovascular Physiologic Phenomena [G09.330.553]

Additional relevant MeSH terms:
Sleep Deprivation
Dyssomnias
Sleep Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Mental Disorders

ClinicalTrials.gov processed this record on July 31, 2014